EMERGENCY:A sibling of a child with Krabbe disease who has not yet been tested is at 25% risk of having the condition. Newborn testing and HSCT before symptom onset is the only effective treatment for infantile Krabbe disease. —call040-46324365immediately — 24 hours, 7 days— 24/7
Krabbe Disease in Hyderabad: When a Baby Becomes Inconsolably Irritable — Why Every Hour Until Diagnosis Matters
Expert GALC enzyme assay, GALC gene sequencing, MRI brain and spine for the GALC fingerprint, nerve conduction studies, urgent newborn and sibling testing, expedited HSCT referral for pre-symptomatic and early-stage late-infantile / juvenile Krabbe, and supportive / palliative management by the KIMS Neuroscience team at KIMS Neuroscience, Secunderabad, Hyderabad.
Krabbe disease (globoid cell leukodystrophy, GLD) is an autosomal recessive lysosomal storage disease caused by GALC gene mutations producing galactocerebrosidase (GALC) deficiency. The key neurotoxic mechanism: without GALC, the intermediate metabolite psychosine (galactosylsphingosine) accumulates and is directly toxic to oligodendrocytes — rapidly destroying them and producing the pathognomonic globoid cells (multinucleated macrophages engulfing myelin debris). Early-infantile Krabbe (~85–90% of cases): onset before 6 months with extreme irritability, hypertonicity, hyperekplexia, rapid deterioration through three stages (irritability/hypertonicity → regression → decerebrate posturing), and death by age 2 without intervention. MRI: cerebellar and corticospinal tract involvement early (unlike MLD which spares the posterior fossa early). Pre-symptomatic HSCT in identified newborns: near-normal development. HSCT given after symptom onset in infantile Krabbe: no meaningful benefit. GALC pseudodeficiency exists and requires gene sequencing for confirmation.
- Psychosine toxicity — the central mechanism
- Galactosylsphingosine (psychosine) is the key neurotoxic metabolite. It accumulates rapidly and is DIRECTLY TOXIC to oligodendrocytes, destroying them far faster than galactocerebroside accumulation alone. This psychosine toxicity is why infantile Krabbe progresses so rapidly and why the HSCT window is so narrow.
- Globoid cells — the pathological hallmark
- Globoid cells are multinucleated macrophages containing engulfed galactocerebroside debris from destroyed myelin. They are the histological hallmark of Krabbe disease. On pathological examination, they are found throughout the white matter at sites of active myelin destruction.
- Three stages of infantile Krabbe
- Stage 1 (3–6 months): extreme, inconsolable irritability + hypertonicity + hyperekplexia. Stage 2 (6–12 months): regression (motor milestones lost), peripheral nerve involvement (reflexes become absent), cortical blindness, seizures. Stage 3: decerebrate posturing, near-vegetative state, inability to swallow, respiratory deterioration. Death typically 13–24 months.
- Cerebellar-first MRI — key difference from MLD
- In early-infantile Krabbe: T2 signal change begins in the CEREBELLAR white matter, corticospinal tracts, internal capsule posterior limb, and optic nerves. MLD primarily spares the posterior fossa early and shows periventricular predominance. This cerebellar early involvement is the key MRI imaging differentiator between Krabbe and MLD.
- HSCT — greatest benefit before symptom onset
- HSCT provides the greatest benefit when performed before symptom onset in infants predicted to have infantile onset Krabbe disease. Once significant neurological symptoms or regression have developed, the benefit is substantially reduced and treatment decisions should be individualized according to age, disease stage and neurological involvement. Newborns identified through family testing or screening and transplanted before any symptom onset develop near-normally in most cases (Escolar et al., NEJM 2005).
- Adult Krabbe — mimics HSP or MS
- Adult-onset Krabbe presents with slowly progressive spastic paraparesis or myelopathy, mimicking hereditary spastic paraplegia or MS. Peripheral neuropathy often present. GALC enzyme testing is the diagnostic test. GALC pseudodeficiency exists (intermediate enzyme activity without disease) — gene sequencing confirms pathogenic mutations.
- Sibling testing is the only meaningful intervention
- The sibling of a child with Krabbe disease has a 25% risk of being affected. Pre-symptomatic identification followed by HSCT before symptom onset produces dramatically better outcomes than any intervention after symptoms begin. Speed of sibling testing matters.
| Fact | Details |
|---|---|
| Mechanism | GALC deficiency (GALC gene) · Psychosine (galactosylsphingosine) directly toxic to oligodendrocytes · Globoid cells = multinucleated macrophages engulfing myelin debris |
| Early-infantile form | ~85–90% of Krabbe · Three stages: extreme irritability (3–6 months) → regression → decerebrate posturing · Death by 13–24 months without intervention |
| MRI — Krabbe vs MLD | Krabbe: cerebellar + corticospinal tracts early, optic nerve, internal capsule · MLD: periventricular predominant, spares posterior fossa early · Key imaging differentiator |
| HSCT timing | Greatest benefit before symptom onset in infants predicted to have infantile onset Krabbe · After significant symptoms or regression the benefit is substantially reduced · Older-onset and late forms: individualise by age, disease stage and neurological involvement |
| GALC pseudodeficiency | Intermediate GALC enzyme activity without disease · GALC gene sequencing confirms pathogenic mutations and excludes pseudodeficiency |
| Adult Krabbe | Slowly progressive spastic paraparesis + peripheral neuropathy · Mimics HSP or MS · GALC enzyme + gene sequencing confirms diagnosis |
| Sibling testing | Highest clinical priority · 25% risk in each sibling · Pre-symptomatic newborn identification is the only meaningful Krabbe intervention |
About This Condition
Krabbe Disease at a Glance
The essential facts that shape how Krabbe disease is recognised, diagnosed, and managed at KIMS — from psychosine toxicity to oligodendrocytes and the autosomal-recessive GALC genetics, to the four age-defined forms and the critical timeline that makes pre-symptomatic identification the only meaningful intervention for infantile Krabbe.
What it is
Krabbe disease (globoid cell leukodystrophy, GLD) is an autosomal recessive lysosomal storage disease caused by deficiency of the enzyme galactocerebrosidase (GALC), encoded by the GALC gene. Without GALC, galactocerebroside — the main lipid of myelin — cannot be degraded. More critically, the intermediate metabolite psychosine (galactosylsphingosine) accumulates and is directly toxic to oligodendrocytes — the cells that produce and maintain myelin. Psychosine toxicity rapidly destroys oligodendrocytes, producing a devastating and rapidly progressive demyelination that characteristically produces the globoid cells (multinucleated macrophages engulfing myelin debris) seen on pathology.
Forms and frequency
Early-infantile Krabbe (onset before 6 months): the most common form, representing approximately 85–90% of all Krabbe disease. Rapidly fatal without intervention, typically by age 2. Late-infantile (6 months–3 years) and juvenile (3–10 years) forms: slower progression, some treated with HSCT with better outcomes. Adult-onset Krabbe: rare, presents with slowly progressive spastic paraparesis or myelopathy, may be misdiagnosed as hereditary spastic paraplegia or MS.
Incidence
Approximately 1 in 100,000 births globally. Higher in specific populations with founder mutations (e.g., Druze population in Israel, some Scandinavian populations). In India, precise incidence data are limited, but cases are seen across the country in consanguineous and non-consanguineous families.
The critical timeline
Early-infantile Krabbe progresses from birth to death within 12–24 months. Symptom onset (typically age 3–6 months) is followed by rapid deterioration. HSCT given before symptom onset (in a newborn sibling identified through family testing or newborn screening) produces dramatically better outcomes than HSCT given after onset. HSCT provides the greatest benefit when performed before symptom onset in infants predicted to have infantile onset Krabbe disease. Once significant neurological symptoms or regression have developed, the benefit is substantially reduced and treatment decisions should be individualized according to age, disease stage and neurological involvement.
Appointment
040-44885000
The Inconsolable Baby
A 4-month-old baby in Hyderabad who was thriving and developing normally becomes increasingly difficult to settle. Within days of onset, she is crying inconsolably for hours. She startles violently to the slightest noise or touch. Her body is becoming stiff — her limbs are extended and tense. She is feeding poorly. Her parents have seen two paediatricians who reassure them it is colic. At KIMS, the clinical picture is immediately concerning.
The combination of extreme, inconsolable irritability, hypertonicity (stiffness), and hyperekplexia (exaggerated startle response) in a previously well infant at 3–4 months is the classic presentation of early-infantile Krabbe disease. MRI brain shows diffuse symmetric white matter signal change with early involvement of the corticospinal tracts in the posterior limbs of the internal capsule and the cerebellar white matter. Nerve conduction studies are severely abnormal. GALC enzyme activity in leukocytes: undetectable. GALC gene sequencing: homozygous pathogenic mutation.
The diagnosis is early-infantile Krabbe disease. The conversation at KIMS is one of the most difficult in paediatric neurology. By the time of symptom onset in early-infantile Krabbe, the window for disease-modifying treatment with HSCT is either closed or closing rapidly. Most infants at this stage have already sustained sufficient neurological damage that HSCT will not prevent severe disability. The goal becomes: the best possible supportive care for this child, and immediate testing and treatment consideration for the 3-year-old sibling at home.
The sibling is tested that week. GALC enzyme activity is severely reduced. He is pre-symptomatic. Within 3 weeks, he is at a specialist paediatric haematology centre undergoing conditioning for HSCT. At age 5, he is running, talking, and attending nursery school. Same disease, different timing, completely different futures.
Book a Consultation
Speak directly with The KIMS Neuroscience team and the KIMS Krabbe specialist team — paediatric neurology, metabolic medicine, neuroradiology, clinical genetics, HSCT referral coordination, palliative medicine, and family counselling under one roof. Sibling and newborn testing arranged urgently. No referral required. Monday to Saturday.
040-44885000Urgent sibling testing: 040-44885000Clinical Features of Early-Infantile Krabbe
The clinical profile of early-infantile Krabbe progresses through three devastating stages — extreme irritability and hypertonicity, severe neurological regression, and decerebrate posturing — alongside the slower late-infantile, juvenile, and adult-onset variants and the GALC fingerprint pattern on MRI.
Stage 1 — extreme irritability and hypertonicity (3–6 months)
The first and most distinctive feature of early-infantile Krabbe is severe, relentless irritability that is qualitatively different from colic or normal infant unsettled behaviour. Parents describe an inconsolable cry that is present even when the baby is fed, held, and warm. Simultaneously, the baby becomes hypertonic — the muscles are abnormally stiff, the limbs extend rigidly when touched. Feeding becomes difficult from oromotor dysfunction. Hyperekplexia: exaggerated startle to sound or touch. This combination in the first 6 months of life is Krabbe disease until proven otherwise.
Stage 2 — severe neurological regression (6–12 months)
The irritability may paradoxically reduce as the nervous system is destroyed further. Motor milestones are lost: sitting, then head control, then swallowing. Peripheral neuropathy becomes evident — deep tendon reflexes, briefly hyperactive in stage 1, become absent as peripheral nerve demyelination advances. Cortical blindness develops. Seizures occur. The infant loses all voluntary movement.
Stage 3 — decerebrate posturing, vegetative state
End-stage early-infantile Krabbe: the infant is in a near-vegetative state, with decerebrate or decorticate posturing, absent voluntary movement, no response to external stimuli, and inability to swallow. Respiratory function deteriorates. Death typically occurs between 13 and 24 months without disease-modifying intervention.
Late-infantile and juvenile Krabbe — slower and more variable
Late-infantile Krabbe (6 months–3 years): regression after initial normal development, then progressive spasticity, ataxia, loss of vision, and intellectual decline. Less rapid than the infantile form. HSCT in symptomatic late-infantile Krabbe has shown some benefit in arresting progression. Juvenile Krabbe (3–10 years): initial presentation may be with vision loss, gait disturbance, or learning difficulties. MRI shows white matter changes. HSCT in early juvenile Krabbe has produced meaningful stabilisation in some patients. Adult Krabbe: progressive spastic paraparesis, peripheral neuropathy, possible dementia. Slowest course; HSCT evidence limited.
MRI findings — the GALC fingerprint
Early-infantile Krabbe: T2 hyperintensity beginning in the posterior limbs of the internal capsule, cerebellar white matter, corticospinal tracts in the brainstem, and deep white matter — following the myelination sequence in reverse. Unlike MLD (which spares the posterior fossa early), cerebellar white matter is affected very early in Krabbe. Optic nerve involvement is also early. Calcifications in the thalami and basal ganglia are seen in some cases on CT.
Diagnosis at KIMS
Diagnosis at KIMS — GALC Enzyme, Gene Sequencing, MRI & NCS
Krabbe disease diagnosis at KIMS combines GALC enzyme activity in leukocytes (the essential first test), GALC gene sequencing (for definitive confirmation and family testing), MRI brain and spine showing the cerebellar and corticospinal-tract pattern characteristic of Krabbe, and nerve conduction studies documenting the dramatic peripheral demyelination.
GALC enzyme assay — the essential first test
GALC (galactocerebrosidase) enzyme activity is measured in leukocytes from peripheral blood. Severely reduced activity (typically less than 5% of normal) confirms Krabbe disease. Some individuals have intermediate GALC activity (pseudodeficiency) without disease — GALC gene sequencing is performed alongside to confirm pathogenic mutations and distinguish true from pseudodeficiency. At KIMS, GALC testing is arranged urgently through a national metabolic reference laboratory.
GALC gene sequencing
Confirms the diagnosis, enables carrier testing of parents and relatives, and allows prenatal diagnosis or preimplantation genetic testing in future pregnancies. More than 130 pathogenic GALC variants are known; compound heterozygosity (two different mutations) is common.
MRI brain and spine
Cerebellar and corticospinal tract involvement early; posterior predominant white matter changes; optic nerve involvement. MRI at KIMS is reviewed with specific attention to the pattern characteristic of Krabbe vs other leukodystrophies. Calcifications in the thalami and basal ganglia may be visible on CT in some cases.
Nerve conduction studies
Severely reduced motor and sensory conduction velocities (demyelinating pattern, often more severe than any other inherited neuropathy). Absent sural sensory response. Combined with central white matter disease, this confirms the pan-demyelinating nature of Krabbe disease.
Treatment
Treatment at KIMS — HSCT & Supportive Management
Treatment of Krabbe disease at KIMS is built around HSCT — the only disease-modifying treatment, with dramatically different outcomes by stage at transplantation — and compassionate supportive and palliative management for children diagnosed after symptom onset, where HSCT no longer benefits.
Pre-symptomatic newborn HSCT, symptomatic infantile outcomes, late-infantile / juvenile early-stage HSCT & supportive care
HSCT works in Krabbe disease by the same mechanism as in MLD: donor-derived macrophages migrate into the CNS and produce GALC enzyme, correcting the metabolic defect. The evidence is stark:
Pre-symptomatic HSCT in newborns: Children identified through newborn screening or family testing before any symptom onset and transplanted within the first month of life develop near-normally in most cases. Long-term follow-up shows these children attending school, walking, and developing language — though some subtle neurological differences persist.
Symptomatic infantile Krabbe: HSCT provides no meaningful clinical benefit once neurological regression has begun. The existing myelin damage cannot be reversed. This is the tragic reality that makes pre-symptomatic identification the only meaningful intervention.
Late-infantile and juvenile Krabbe (early stage): HSCT in symptomatic but early-stage late-infantile and juvenile forms has produced stabilisation or slowing of progression in some patients. KIMS assesses and refers these patients to HSCT centres.
Supportive and Palliative Management at KIMS: For the majority of Indian infants with Krabbe disease who are diagnosed after symptom onset: seizure management (clonazepam for myoclonic seizures; levetiracetam or valproate for tonic-clonic), spasticity management (baclofen), management of the hyperekplexia (clonazepam is also useful), nutrition via nasogastric or gastrostomy tube when oral feeding fails, physiotherapy for comfort and positioning, pain management, and family support with palliative care integration.
Related Conditions
Krabbe disease belongs to the family of hereditary polyneuropathies and leukodystrophies evaluated and managed at KIMS Neuroscience:
FAQs
Frequently Asked Questions
An inconsolable infant becoming stiff. A newborn sibling of a child with Krabbe disease who has not yet been tested. A diagnosis that arrives after the treatment window has closed — or one that arrives just in time.
At KIMS Neuroscience, Secunderabad, Hyderabad, GALC enzyme testing, MRI, and NCS are arranged urgently for any suspected Krabbe case, and sibling testing is given the highest clinical priority. Call 040-44885000 to book a Krabbe assessment. Urgent sibling testing: 040-44885000.
International enquiries: info@kimsneurosciences.com